Tag: Avenue Therapeutics


The FDA Sends A Complete Response Letter To Avenue Therapeutics For IV Tramadol

Avenue Therapeutics (NASDAQ: ATXI) (“Avenue”) is a company that develops intravenous Tramadol IV for the United States market, and it recently received its second CRL (Complete Response Letter) from the FDA regarding its New Drug Application which requested approval for Tramadol IV. The Complete Response Letter stated that the unpredictable […]